Correction: High Vascular Delivery of EGF, but Low Receptor Binding Rate Is Observed in AsPC-1 Tumors as Compared to Normal Pancreas (Molecular Imaging and Biology, (2012), 14, 4, (472-479), 10.1007/s11307-011-0503-5);High vascular delivery of EGF, but low receptor binding rate is observed in AsPC-1 tumors as compared to normal pancreas

Molecular Imaging and Biology

Volumn 14, Issue 4, 2012, Pages 472-479

  Samkoe, Kimberley S ^a   Sexton, Kristian ^a   Tichauer, Kenneth M ^a   Hextrum, Shannon K ^a   Pardesi, Omar ^a   Davis, Scott C ^a   O'Hara, Julia A ^a   Hoopes, P Jack ^a,b   Hasan, Tayyaba ^c   Pogue, Brian W ^a,b,c  

^a DARTMOUTH COLLEGE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cellular associated rate constant; Epidermal growth factor receptor; Fluorescence imaging; Pancreatic tumor; Three compartment model

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCENT DYE; IRDYE800CW; IRDYE800CW EPIDERMAL GROWTH FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING KINETICS; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; EX VIVO STUDY; EXCRETION; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 84865488491     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-023-01862-1     Document Type: Erratum

References (30)

1. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147-1157 (Pubitemid 41486396)
2. Kovar JL, Simpson MA, Schutz-Geschwender A, Olive DM (2007) A systematic approach to the development of fluorescent contrast agents for optical imaging of mouse cancer models. Anal Biochem 367:1-12 (Pubitemid 46938663)
3. Achilefu S, Dorshow RB, Bugaj JE, Rajagopalan R (2000) Novel receptor-targeted fluorescent contrast agents for in vivo tumor imaging. Invest Radiol 35:479-485 (Pubitemid 30622015)
4. Becker A, Hessenius C, Licha K et al (2001) Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol 19:327-331 (Pubitemid 32275340)
5. Durkin AJ, Bloomston PM, Rosemurgy AS et al (2003) Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am J Surg 186:431-436 (Pubitemid 37352823)
6. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 90:1352-1360
7. Baker CH, Solorzano CC, Fidler IJ (2003) Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 62:1996-2003
8. Bruns CJ, Solorzano CC, Harbison MT et al (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60:2926-2935 (Pubitemid 30395817)
9. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
10. Xiong HQ, Rosenberg A, LoBuglio A et al (2004) Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 22:2610-2616 (Pubitemid 41103748)
11. Graeven U, Kremer B, Sudhoff T et al (2006) Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 94:1293-1299
12. Samkoe KS, Hextrum SK, Pardesi O, O'Hara JA, Hasan T, Pogue BW (2010) Specific binding of molecularly targeted agents to pancreas tumors and impact on observed optical contrast. Proc SPIE 7568:75680H
13. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME (2007) Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci 104:15549-15554 (Pubitemid 47502954)
14. Pogue BW, Samkoe KS, Hextrum S et al (2010) Imaging targeted-agent binding in vivo with two probes. J Biomed Opt 15:030513
15. Innis RB, Cunningham VJ, Delforge J et al (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539 (Pubitemid 47301451)
16. Samkoe KS, Chen A, Rizvi I et al (2010) Imaging tumor variation in response to photodynamic therapy in pancreatic cancer xenograft models. Int J Radiat Oncol Biol Phys 76:251-259
17. Samkoe KS, Sexton K, Tichauer K et al (2011) Determination of blood plasma fluorescence extinction coefficients for dyes used in threecompartment binding model. Proc SPIE 7886:78860A
18. Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425-1433 (Pubitemid 41222414)
19. Velikyan I, Sundberg ÖL, Lindhe Ñ et al (2005) Preparation and evaluation of 68 Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med 46:1881-1888 (Pubitemid 46196651)
20. Adams KE, Ke S, Kwon S et al (2007) Comparison of visible and nearinfrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt 12
21. Laruelle M, Baldwin RM, Rattner Z et al (1994) SPECT quantification of I-123 Iomazenil binding to benzodiazepine receptors in nonhumanprimates: 1. Kinetic modeling of single bolus experiments. J Cereb Blood Flow Metab 14:439-452
22. Tofts PS, Kermode AG (1991) Measurement of the blood-brain-barrier permeability and leakage space using dynamic MR imaging: 1. Fundamental- concepts. Magn Reson Med 17:357-367
23. Smith JJ, Derynck R, Korc M (1987) Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci 84:7567-7570
24. Kovar JL, Johnson MA, Volcheck WM, Chen J, Simpson MA (2006) Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model. Am J Pathol 169:1415-1426 (Pubitemid 351194374)
25. Zhou M, Felder S, Rubinstein M et al (1993) Real-time measurements of kinetics of EGF binding to soluble EGF receptor monomers and dimers support the dimerization model for receptor activation. Biochemistry 32:8193-8198 (Pubitemid 23265809)
26. Robertson MW, Leslie CA, Bennett JP (1991) Apparent synaptic dopamine deficiency induced by withdrawal from chronic cocaine treatment. Brain Res 538:337-339
27. Kallinowski F, Schlenger KH, Runkel S et al (1989) Blood-flow, metabolism, cellular microenvironment, and growth-rate of humantumor xenografts. Cancer Res 49:3759-3764 (Pubitemid 19197393)
28. Herholz K, Rudolf J, Heiss W-D (1992) FDG transport and phosphorylation in human gliomas measured with dynamic PET. J Neuro-Oncol 12:159-165
29. Okazumi S, Isono K, Enomoto K et al (1992) Evaluation of liver tumors using fluorine- 18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med 33:333-339
30. Korc M (2007) Pancreatic cancer-associated stroma production. Am J Surg 194:S84-S86 (Pubitemid 47454597)